ArticleCancer medicine2024

Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission.

Xi Jia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.